Pharmaceuticals - Community Register

  

List of nationally authorised medicinal products for human use

Tazocin and associated names

Product name: Tazocin and associated names
Also marketed in the EU under the name(s): Tazobac, Tazocel, Tazocilline, Tazocin, Tazonam
Active substance: piperacillin-tazobactam
Indication: Tazocin is indicated for the treatment of the following infections
- Adults and adolescents
- Severe pneumonia including hospital acquired and ventilator associated pneumonia
- Complicated urinary tract infections (including pyelonephritis)
- Complicated intra abdominal infections
- Complicated skin and soft tissue infections (including diabetic foot infections)
Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
Tazocin may be used in the management of neutropenic patients with fever suspected to be due to a bacterial infection.
- Children 2 to 12 years of age
- Complicated intra-abdominal infections
Tazocin may be used in the management of neutropenic children with fever suspected to be due to a bacterial infection.
Marketing Authorisation Holder: Pfizer Limited

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
23/02/2011 Referral EMEA/H/A-30/1149 (2011)1196 of 21/02/2011